Harmony Biosciences Holdings, Inc. (HRMY)
| Market Cap | 2.08B |
| Revenue (ttm) | 270.52M |
| Net Income (ttm) | 11.68M |
| Shares Out | 58.47M |
| EPS (ttm) | 0.20 |
| PE Ratio | 181.73 |
| Forward PE | 22.42 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 134,099 |
| Open | 36.38 |
| Previous Close | 36.68 |
| Day's Range | 35.00 - 36.49 |
| 52-Week Range | 25.09 - 45.89 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 57.00 (+60.0%) |
| Earnings Date | Nov 9, 2021 |
About HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvani...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for HRMY stock is "Buy." The 12-month stock price forecast is 57.00, which is an increase of 60.02% from the latest price.
News
Harmony Biosciences to Participate in 40th Annual J.P. Morgan Healthcare Conference
PLYMOUTH MEETING, Pa., Jan. 5, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi...
Harmony Biosciences to be Added to the Nasdaq Biotech Index
PLYMOUTH MEETING, Pa., Dec. 17, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...
Harmony Biosciences Publishes Pitolisant Efficacy Data In CNS Drugs
PLYMOUTH MEETING, Pa., Dec. 13, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...
Harmony Biosciences Announces Plans To Initiate Phase 3 Clinical Trial For Treatment Of Idiopathic Hypersomnia
PLYMOUTH MEETING, Pa., Dec. 1, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi...
Harmony Biosciences Appoints Linda Szyper To Its Board Of Directors
PLYMOUTH MEETING, Pa., Nov. 22, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing ...
Harmony Biosciences To Participate In Two Investor Conferences In November
PLYMOUTH MEETING, Pa., Nov. 11, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...
Harmony Biosciences Holdings, Inc. (HRMY) Tops Q3 Earnings and Revenue Estimates
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 88.89% and 1.81%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead f...
Harmony Biosciences Reports Third Quarter 2021 Financial Results and Business Updates
WAKIX® (pitolisant) Net Revenue of $80.7 Million for Third Quarter 2021 Increase of 77% vs. the Same Period in 2020
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Harmony Biosciences Holdings, Inc. (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harmony Biosciences Announces Date of Third Quarter 2021 Financial Results
PLYMOUTH MEETING, Pa., Oct. 26, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing ...
Harmony Biosciences to be Added to the S&P SmallCap 600® Index
PLYMOUTH MEETING, Pa., Oct. 21, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing ...
Harmony Biosciences Holdings, Inc. (HRMY) Surges 10.2%: Is This an Indication of Further Gains?
Harmony Biosciences Holdings, Inc. (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving hig...
Why Harmony Biosciences Stock Is Up 15% Today
The young biopharma outfit is set to become part of a major market index, which means a buying spree is on the radar.
Kite Realty Group Trust Set to Join S&P MidCap 400; Harmony Biosciences Holdings & LendingTree to Join S&P SmallCap 600
NEW YORK, Oct. 18, 2021 /PRNewswire/ -- S&P SmallCap 600 constituent Kite Realty Group Trust (NYSE:KRG) will replace LendingTree Inc. (NASD:TREE) in the S&P MidCap 400, LendingTree will replace Kite Rea...
5 Stocks for Higher Returns as Analysts Initiate Coverage
Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like Alpha and Omega (AOSL), Preferred Apartment (APTS), Hut 8 Mining (HUT), GCM (GCMG) & Harmony Bio...
Harmony Biosciences Announces Winners of Patients at the Heart and Progress at the Heart on Third Annual World Narcol...
PLYMOUTH MEETING, Pa., Sept. 22, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...
Harmony Biosciences To Participate In Three Investor Conferences In September
PLYMOUTH MEETING, Pa., Sept. 2, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...
Harmony Biosciences Stock Is Trading Higher On $330M Financing Deal With Blackstone, Q2 Earning Beat Estimates
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) has entered into a $330 million financing collaboration with The Blackstone Group Inc (NYSE: BX). The financing deal includes up to $300 million in debt c...
Harmony Biosciences Reports Second Quarter 2021 Financial Results and Business Updates
WAKIX® (pitolisant) Net Revenue of $73.8 Million for Second Quarter 2021 vs. $38 Million for the Same Period in 2020
Harmony Biosciences And Blackstone Enter Into Strategic Financing Collaboration
PLYMOUTH MEETING, Pa. and NEW YORK, Aug. 10, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing inno...
Harmony Biosciences Acquires Asset With Novel Mechanism Of Action For The Potential Treatment Of Narcolepsy And Other...
PLYMOUTH MEETING, Pa., Aug. 9, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi...
John C. Jacobs, President And CEO Of Harmony Biosciences, Named An Ernst & Young (EY) Entrepreneur Of The Year 2021 G...
PLYMOUTH MEEETING, Pa., July 29, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...
Harmony Biosciences Announces Date Of Second Quarter 2021 Financial Results
PLYMOUTH MEETING, Pa., July 27, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing ...
Harmony Biosciences Initiates A Phase 2 Clinical Trial In Myotonic Dystrophy
PLYMOUTH MEETING, Pa., June 29, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...
Harmony Biosciences Presents New Analysis Of Clinical Impact For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting
PLYMOUTH MEETING, Pa., June 10, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...